GMP
Gyeonggi do, South Korea
GMP
Gyeonggi do, South Korea

Time filter

Source Type

News Article | February 28, 2017
Site: www.businesswire.com

ROLLING MEADOWS, Ill.--(BUSINESS WIRE)--Plumbing Manufacturers International (PMI) is focusing its 2017 advocacy on a series of efforts intended to educate policymakers about the untapped water-saving potential of water-efficient plumbing products, potential threats to safe drinking water, and the need for a restored national water infrastructure. While communications between PMI and policymakers about these issues are ongoing, CEOs and other top executives from PMI member companies will meet with legislative leaders during PMI’s Executive Forums and Fly-Ins planned for June 13-14 in Sacramento, Calif., and late summer or fall in Washington, D.C. In addition, PMI CEO/Executive Director Barbara C. Higgens is available for background or comment on any of the following issues: PMI and the Alliance for Water Efficiency (AWE) have a study in progress to determine potential water savings that could be achieved by replacing older, inefficient toilets with water-efficient models. With results due in spring 2017, the “Saturation Study of Non-Efficient Water Closets in Key States” is focused on Arizona, California, Colorado, Georgia and Texas – all states that have experienced serious water shortages. This research follows up a 2015 PMI/GMP Research, Inc., study of water-efficient toilets, showerheads and faucets installed nationwide. Another PMI study, now in progress under the direction of Dr. Paul Sturman of Montana State University, will test the hypothesis that low flow rates yield a greater proliferation of opportunistic waterborne pathogens, such as legionella, in potable water and create unsafe conditions. The results of this study also are expected this spring. PMI is also awaiting with interest the results of a Virginia Tech study under the direction of Drs. Amy Pruden and Marc Edwards that is exploring the relative abundance and diversity of antibiotic-resistant genes and pathogens in reclaimed (recycled) versus potable water distribution systems. With results due in spring 2017, this study is particularly relevant given plans in California to expand the installation of recycled water systems that use non-potable water in toilets and urinals and with personal hygiene devices (bidet seats) installed by consumers after construction. Virginia Tech researchers also recently released the results of a study concluding that interrupted corrosion control caused the Flint water crisis. With an aging underground water infrastructure having been identified as a contributor to lead-in-water crises in Flint and other locations, Congressional leaders from both parties have expressed interest in developing job-creating legislation that would restore American infrastructure. PMI will be urging Congress to address water infrastructural concerns through this legislation. Last summer, PMI introduced its water infrastructure advocacy through a position paper and infographic. Plumbing Manufacturers International is the voluntary, not-for-profit international industry association of manufacturers of plumbing products, serving as the Voice of the Plumbing Industry. Member companies produce 90 percent of the nation’s plumbing products. As part of its mission, PMI advocates for plumbing product performance and innovation contributing to water savings, sustainability, public health and safety, and consumer satisfaction. For more information on PMI or its conferences, contact the organization at 1921 Rohlwing Road, Unit G, Rolling Meadows, IL, 60008; tel.: 847-481-5500; fax: 847- 481-5501. www.safeplumbing.org.


STONEY CREEK, ON / ACCESSWIRE / February 17, 2017 / Today, CanniMed Therapeutics Inc. (TSX: CMED) and CTT Pharmaceutical Holdings Inc. (OTC PINK: CTTH) have entered into a definitive contractual relationship for the licensing of CTT's Orally Dissolvable Thin Film (ODF) Wafer technology. "We are excited to announce the closing of our licensing agreement with CanniMed Therapeutics Inc. and we believe that we have found the best partner to commercialize our proprietary drug delivery technology in Canada and potentially abroad," said Dr. Pankaj Modi, President and CEO, CTT Pharmaceutical Holdings. "The execution of the CanniMed agreement marks an important first step in the relaunch of CTT Pharma and moving forward we intend to penetrate the United Sates on a state-by-state basis, identifying what we feel are the best partners in each location and to address those markets. We hope to be able to update shareholders on incremental progress soon and we are committed to improving our shareholder communications and increasing our transparency as a public entity." Dr. Modi continued, "CTT is currently in discussions with a number of licensed producers across the majority of the legal medicinal and recreational markets in the United States with demonstrated interest from industry leading players regarding the ability to bring our offering into their suite of products. As we move forward, the Company is considering licensing agreements, joint ventures and vertical integration opportunities as the likely means to bring our product to market in the way that will generate the best economic return to the shareholders of CTT." "The CanniMed ODF Wafers will complement the already well-integrated line of CanniMed® Oil products we have in market, broadening our ability to provide patients with standardized, dose-sensitive and discrete delivery systems," said Brent Zettl, President and CEO, CanniMed Therapeutics Inc. "Collaborations with innovative companies such as CTT Pharma, and continued research and development into products that will further position medical cannabis as an important therapeutic option is a core focus of our company." Orally Dissolvable Thin Film (ODF) Wafers are a proprietary drug delivery mechanism in the form of paper-thin polymer films used as carriers for several pharmaceutical agents, for which the Company has patented Cannabinoid and Opioid delivery for pain management. In this innovative format, the drug is taken orally but does not require water or swallowing. ODF Wafers dissolve quickly in the oral cavity (5-15 seconds) ensuring that the active ingredient is rapidly absorbed and diffused into the dense network of capillaries for direct access to the bloodstream via the oral mucosa. The active ingredient, once absorbed, bypasses the liver's first-pass effect and effectively improves bioavailability and facilitates excellent patient compliance. This industry-first collaboration will enable CTT Pharmaceuticals to develop and commercialize its novel, smoke-free delivery system throughout Canada by leveraging CanniMed's embedded market position and existing medicinal cannabis patient population. Orally Dissolvable Thin Film Wafers improve therapeutic outcome and efficacy through immediate onset of action in a convenient and discrete delivery. As a smoke-free alternative, ODF Wafers are suitable for a wide range of potential consumers, from geriatrics to pediatric patients who experience difficulty swallowing or patients who suffer from Phagophobia (fear of swallowing) or Pnigophobia (fear of choking). Following the execution of the Licensing Agreement, CTT was paid $40,000USD by CMED. Upon issuance of the license from Health Canada to begin development of the OTF-cannabis wafer, CTT will be paid $935,000USD. CTT will also receive a royalty of 5 per cent based on gross sales. Additional payments will be made to CTT upon reaching certain milestones to be negotiated between the parties. CTT's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases, including pain management. The Oral Thin Film (Wafer) formulation is protected by several Canadian and US Patents. CTT's oral fast dissolving drug delivery systems will consist of edible thin films (wafers) that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing. Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its Wafer technology will be one of the first to gain use in major markets, such as pain management. For more information, please visit our website: www.cttpharmaceuticals.com The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant plant production processes and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMed Ltd., a wholly-owned subsidiary of the Company, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. Prairie Plant Systems Inc., a wholly-owned subsidiary of the Company, was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion. For more information, please visit our websites: www.cannimed.ca (patients) and www.CanniMedTherapeutics.com (investors). This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "plans," "expects," or "does not expect," "is expected," "estimates," "intends," "anticipates," or "does not anticipate," or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," or "will" be taken, occur or be achieved. Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including our future sales, income and financial position. The forward-looking statements included in this news release are made as of the date of this news release and CTT Pharmaceutical Holdings not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities law. For more information or to schedule an interview, please contact: STONEY CREEK, ON / ACCESSWIRE / February 17, 2017 / Today, CanniMed Therapeutics Inc. (TSX: CMED) and CTT Pharmaceutical Holdings Inc. (OTC PINK: CTTH) have entered into a definitive contractual relationship for the licensing of CTT's Orally Dissolvable Thin Film (ODF) Wafer technology. "We are excited to announce the closing of our licensing agreement with CanniMed Therapeutics Inc. and we believe that we have found the best partner to commercialize our proprietary drug delivery technology in Canada and potentially abroad," said Dr. Pankaj Modi, President and CEO, CTT Pharmaceutical Holdings. "The execution of the CanniMed agreement marks an important first step in the relaunch of CTT Pharma and moving forward we intend to penetrate the United Sates on a state-by-state basis, identifying what we feel are the best partners in each location and to address those markets. We hope to be able to update shareholders on incremental progress soon and we are committed to improving our shareholder communications and increasing our transparency as a public entity." Dr. Modi continued, "CTT is currently in discussions with a number of licensed producers across the majority of the legal medicinal and recreational markets in the United States with demonstrated interest from industry leading players regarding the ability to bring our offering into their suite of products. As we move forward, the Company is considering licensing agreements, joint ventures and vertical integration opportunities as the likely means to bring our product to market in the way that will generate the best economic return to the shareholders of CTT." "The CanniMed ODF Wafers will complement the already well-integrated line of CanniMed® Oil products we have in market, broadening our ability to provide patients with standardized, dose-sensitive and discrete delivery systems," said Brent Zettl, President and CEO, CanniMed Therapeutics Inc. "Collaborations with innovative companies such as CTT Pharma, and continued research and development into products that will further position medical cannabis as an important therapeutic option is a core focus of our company." Orally Dissolvable Thin Film (ODF) Wafers are a proprietary drug delivery mechanism in the form of paper-thin polymer films used as carriers for several pharmaceutical agents, for which the Company has patented Cannabinoid and Opioid delivery for pain management. In this innovative format, the drug is taken orally but does not require water or swallowing. ODF Wafers dissolve quickly in the oral cavity (5-15 seconds) ensuring that the active ingredient is rapidly absorbed and diffused into the dense network of capillaries for direct access to the bloodstream via the oral mucosa. The active ingredient, once absorbed, bypasses the liver's first-pass effect and effectively improves bioavailability and facilitates excellent patient compliance. This industry-first collaboration will enable CTT Pharmaceuticals to develop and commercialize its novel, smoke-free delivery system throughout Canada by leveraging CanniMed's embedded market position and existing medicinal cannabis patient population. Orally Dissolvable Thin Film Wafers improve therapeutic outcome and efficacy through immediate onset of action in a convenient and discrete delivery. As a smoke-free alternative, ODF Wafers are suitable for a wide range of potential consumers, from geriatrics to pediatric patients who experience difficulty swallowing or patients who suffer from Phagophobia (fear of swallowing) or Pnigophobia (fear of choking). Following the execution of the Licensing Agreement, CTT was paid $40,000USD by CMED. Upon issuance of the license from Health Canada to begin development of the OTF-cannabis wafer, CTT will be paid $935,000USD. CTT will also receive a royalty of 5 per cent based on gross sales. Additional payments will be made to CTT upon reaching certain milestones to be negotiated between the parties. CTT's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases, including pain management. The Oral Thin Film (Wafer) formulation is protected by several Canadian and US Patents. CTT's oral fast dissolving drug delivery systems will consist of edible thin films (wafers) that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing. Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its Wafer technology will be one of the first to gain use in major markets, such as pain management. For more information, please visit our website: www.cttpharmaceuticals.com The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant plant production processes and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMed Ltd., a wholly-owned subsidiary of the Company, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. Prairie Plant Systems Inc., a wholly-owned subsidiary of the Company, was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion. For more information, please visit our websites: www.cannimed.ca (patients) and www.CanniMedTherapeutics.com (investors). This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "plans," "expects," or "does not expect," "is expected," "estimates," "intends," "anticipates," or "does not anticipate," or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," or "will" be taken, occur or be achieved. Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including our future sales, income and financial position. The forward-looking statements included in this news release are made as of the date of this news release and CTT Pharmaceutical Holdings not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities law. For more information or to schedule an interview, please contact:


News Article | February 15, 2017
Site: en.prnasia.com

TAINAN, Taiwan, Feb. 15, 2017 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2016. The consolidated revenue was NT$4.031 billion (US$125 million), after-tax net profits were NT$659 million (US$20.4 million). The after-tax earnings per share was NT$0.87 (US$0.027). In 2016, overall revenue increased by 2% compared to 2015 primarily as a result of the sales boost of generic APIs, including an increased market share of Gemcitabine combined with more flexible strategies, increased shipments of Paclitaxel, as well as greater customer needs of Entecavir (HBV) and Riluzole (ALS) in anticipation for commercial launch. In terms of contract research services (CRO), several customers have achieved favorable clinical results in their Phase III trials, suggesting an increased shipment volumes and revenues. Meanwhile, revenue from contract manufacturing services (CMO) suffered a sharp reduction due to lower order volume of anti-depressants and anti-obesity drugs, but the overall performance of 2016 has been promising. Increased profit is evident in an overall gross profit margin of 45%; this is a result of a favorable blend of products and clients, especially with increased sales volume of higher profit oncology products and CRO projects. The strategic entry of oncology API Gemcitabine also contributed strongly in the company's gross margin increase. ScinoPharm also demonstrated profitability improvement by tighter cost control, process optimization, and enhanced management efficiency. ScinoPharm continues to pursue strategic alliances in order to enhance its position as a developer and manufacturer of innovative products with high added value. Currently, two ANDA submissions have been filed: an oncology injectable drug jointly developed with U.S.-based SAGENT Pharmaceuticals, and ScinoPharm-developed Fondaparinux. Product partnerships based on co-development and profit-sharing models have been established for eleven products. Furthermore, ScinoPharm is currently negotiating with major international companies for exclusive distribution rights in Europe and the U.S for the drug products indicated for cancer, multiple sclerosis, osteoporosis, diabetes mellitus, etc. To this end, investments were made to enable a GMP-compliant manufacturing plant for injectable products. The injectable plant is being positioned to prepare its first registration batch this year, file ANDA submission by the end of 2018, and expect a USFDA on-site inspection in 2019. The Changshu site in Jiangsu, China, initiated full-scale operations, contributing to ScinoPharm's overall revenues. In efforts to expand the existing CRAM business operations, the company is focusing on mid- to late-phase projects. The current portfolio includes agents in the indications of oncology, anti-hypertension, diabetes, and other therapeutics. The Changshu site is also seeking large-volume generic APIs and intermediates to increase production utilization and is exploring partnerships with generic formulation firms to maximize market share in China via joint development and registration. Oncology products continue to be the mainstay of the company's portfolio. The three primary products in the last year include Paclitaxel for ovarian, lung, and breast cancer, Irinotecan for colorectal cancer, and Gemcitabine for small cell lung and breast cancer. These three products retained ScinoPharm's market share dominance worldwide, which reaffirms the company position as a global leader in oncology product supply. ScinoPharm's regulatory presence in oncology is demonstrated and strengthened by the number of completed drug master files (DMF): The Company has applied for 733 DMFs worldwide, including 55 in the US. Of the 55 US DMFs, 32 are for oncology products. This is an unparalleled number of total DMFs among the independent global providers of APIs and proof of the company's persistent efforts in oncology products. To date, ScinoPharm has developed 72 generic APIs, including 25 marketed products. Numerous others are awaiting the subsequent expiration of active patents. In 2017, ScinoPharm anticipates launching 2 APIs for generic, 1 API for CMO project, and 1 co-developed generic injectable drug, primarily in the US and European markets. These drugs are for the indications of polyuria, benign prostatic hyperplasia, infections, and oncology. ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities for brand companies as well as APIs for the generic industry. The Company also is aggressively pursuing a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of sterile oncology injectable formulations. For more information, please visit the Company's website at http://www.scinopharm.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scinopharm-reports-financial-performance-for-2016-300406864.html


News Article | February 15, 2017
Site: www.marketwired.com

Valener Inc. (« Valener ») (TSX:VNR) (TSX:VNR.PR.A), véhicule d'investissement pour le public dans Société en commandite Gaz Métro (« Gaz Métro »), a annoncé aujourd'hui qu'elle a réalisé un bénéfice net ajusté attribuable aux actionnaires ordinaires de 20,3 millions $ pour le premier trimestre de l'exercice 2017, en hausse de 3,5 millions $, ou 20,8 %, comparativement au premier trimestre de l'exercice 2016, ce qui se traduit par un bénéfice net ajusté de 0,52 $ par action ordinaire pour le premier trimestre de l'exercice 2017 comparativement à 0,44 $ par action ordinaire pour le premier trimestre de l'exercice 2016. Cette progression s'explique par une augmentation marquée du bénéfice net ajusté de Gaz Métro. Le bénéfice net attribuable aux actionnaires ordinaires s'est élevé à 23,0 millions $ pour le premier trimestre de l'exercice 2017, comparativement à 39,4 million $ au premier trimestre de l'exercice 2016. Ceci s'explique principalement par un ajustement ponctuel comptable découlant de l'application des PCGR au premier trimestre de l'exercice 2016, partiellement atténuée par l'augmentation marquée du bénéfice net ajusté de Gaz Métro ainsi que le gain réalisé sur une réévaluation à la suite d'une acquisition au premier trimestre de l'exercice 2017. Valener a généré des liquidités provenant de l'exploitation normalisées de 12,2 millions $ (0,32 $ par action ordinaire) au cours du premier trimestre de l'exercice 2017, comparativement à 10,4 millions $ pour le trimestre correspondant de l'exercice 2016 (0,27 $ par action ordinaire). Cette augmentation s'explique principalement par l'augmentation des distributions reçues de Gaz Métro en raison de : « Le portefeuille réglementé et diversifié de Gaz Métro, investissement principal de Valener, ainsi que sa croissance progressive que nous continuons à soutenir, a directement contribué aux excellents résultats du premier trimestre », souligne Pierre Monahan, président du conseil d'administration de Valener. Parcs éoliens de la Seigneurie de Beaupré 2 et 3, Société en nom collectif (« Parcs 2 et 3 ») ainsi que Parc éolien de la Seigneurie de Beaupré 4 S.E.N.C. (« Parc 4 ») ont globalement généré 3 % de plus d'électricité au cours du premier trimestre de l'exercice 2017, comparativement au premier trimestre de l'exercice 2016. Ils ont par ailleurs généré des flux de trésorerie liés aux activités d'exploitation totalisant 15,8 millions $, comparativement à 18,1 millions $ au cours du premier trimestre de l'exercice 2016 (excluant un paiement de 12,9 millions $ reçu d'Hydro-Québec). Cette baisse s'explique principalement par un décalage entre les revenus et les encaissements. Le bénéfice net ajusté attribuable aux associés de Gaz Métro, lequel exclut des éléments d'ajustements ponctuels, s'est établi à 88,9 millions $ pour le premier trimestre de l'exercice 2017, en hausse de 13,6 millions $, ou 18,1 %, par rapport au premier trimestre de l'exercice 2016. Cette augmentation s'explique principalement par l'augmentation des volumes distribués par la distribution de gaz naturel au Québec (« Gaz Métro-daQ ») en raison de températures plus froides qu'au premier trimestre de l'exercice 2016, par l'augmentation du bénéfice net réalisé par le secteur de la distribution d'énergie au Vermont, notamment en raison de la hausse de la base de tarification de Green Mountain Power Corporation (« GMP ») et du décalage entre le profil de reconnaissance des revenus et des coûts de Gaz Métro-daQ et GMP. « Gaz Métro a entamé un nouvel exercice sur des assises fermes. Les excellents résultats de Gaz Métro-daQ et la croissance des investissements au Québec et au Vermont ont été les forces motrices de l'augmentation du bénéfice net ajusté de près de 20 % », explique Sophie Brochu, présidente et chef de la direction de Gaz Métro. « De plus, avec l'acquisition de la participation de notre partenaire dans CCUM, nous devenons l'unique propriétaire de cet actif stratégique qui nous permet de desservir, via des réseaux de chaleur et de froid, les besoins énergétiques de plusieurs grands édifices phares au centre-ville de Montréal où circulent chaque jour environ 100 000 personnes », a-t-elle poursuivi. Le bénéfice net attribuable aux associés de Gaz Métro s'est quant à lui élevé à 101,4 millions $ au premier trimestre de l'exercice 2017, comparativement à 154,6 millions $ pour le premier trimestre de l'exercice 2016. Cette baisse s'explique principalement par l'effet d'un traitement réglementaire lié aux avantages sociaux futurs de 79,3 millions $ comptabilisé au premier trimestre de l'exercice 2016, partiellement compensé par les éléments mentionnés ci-dessus ainsi que par un gain de 12,5 millions $ sur la réévaluation à la suite d'une acquisition. Le bénéfice net ajusté attribuable aux associés provenant de Gaz Métro-daQ s'est élevé à 64,1 millions $ au premier trimestre de l'exercice 2017, en hausse de 10,7 millions $ par rapport au premier trimestre de l'exercice 2016. L'augmentation de 20 %, est principalement attribuable : Le bénéfice net attribuable aux associés de Gaz Métro-daQ s'est également élevé à 64,1 millions $ au premier trimestre de l'exercice 2017, tandis que celui du trimestre correspondant de l'exercice précédent avait été de 132,7 millions $, reflétant la comptabilisation de l'effet favorable de la constatation d'actifs réglementaires liés aux avantages sociaux futurs de 79,3 millions $. En décembre 2016, Gaz Métro-daQ a complété la mise en service d'un tronçon de 72 km dans la région de Bellechasse. L'approbation de la Régie avait été obtenue en décembre 2015 et consiste au prolongement du réseau entre les municipalités de Lévis et de Sainte-Claire. Compte tenu de la période hivernale, la finalisation du projet, comprenant principalement des travaux de réfections des terrains, sera complétée au printemps 2017. Le secteur Distribution d'énergie au Vermont, par l'entremise de GMP et Vermont Gas Systems (« VGS »), a réalisé un bénéfice net attribuable aux associés de 20,4 millions $ pour le premier trimestre de l'exercice 2017, en hausse de 2,1 millions $, ou 11,5 %, par rapport au premier trimestre de l'exercice 2016 principalement en raison : partiellement atténué par l'effet défavorable de l'arrêt de la capitalisation du rendement sur les investissements non inclus dans la base de tarification de VGS liés au projet Addison, depuis le 1er janvier 2016, en lien avec le protocole d'entente avec le Vermont Public Service Board qui fixe les coûts du projet à 134,0 millions $ US. Chez GMP, le processus réglementaire entourant l'acquisition des petites centrales hydroélectriques d'Enel Green Power North America Inc. suit son cours et nous anticipons la clôture au cours du troisième trimestre de l'exercice 2017. VGS a mis en service le premier tronçon de 17 km du projet Addison en février 2016 et demeurait en attente d'une décision de la Cour suprême du Vermont afin de compléter les travaux devant mener à la mise en gaz de 49 kilomètres de nouvelles conduites. En décembre 2016, la Cour suprême du Vermont a autorisé VGS à poursuivre les travaux sans se prononcer sur le fond de l'appel. Depuis, VGS se prépare à réaliser la construction du dernier kilomètre restant du deuxième tronçon et à finaliser le projet. La mise en gaz est prévue au cours du printemps 2017. Le bénéfice net attribuable aux associés du secteur Transport de gaz naturel s'est élevé à 4,9 millions $ pour le premier trimestre de l'exercice 2017, en hausse de 0,4 million $ par rapport au premier trimestre de l'exercice 2016. Le secteur Production d'électricité a réalisé un bénéfice net attribuable aux associés de 0,8 million $ pour le premier trimestre de l'exercice 2017, comparativement à 0,5 million $ au trimestre correspondant de l'exercice 2016. La hausse s'explique par une augmentation de la production des parcs éoliens, tel que décrit précédemment, étant donné les vents observés qui ont été supérieurs au cours du premier trimestre de l'exercice 2017. Le secteur Services énergétiques, entreposage et autres a réalisé un bénéfice net ajusté attribuable aux associés de 1,0 million $ au premier trimestre de l'exercice 2017, comparable au premier trimestre de l'exercice 2016. Ceci reflète une augmentation marquée des volumes de ventes de GNL, ceux-ci ayant plus que doublés depuis le premier trimestre de l'exercice 2016, pour s'établir à 8,82 millions de mètres cube, atténué en partie par une hausse des dépenses d'exploitation. De plus, la construction du deuxième train de liquéfaction à notre usine de liquéfaction, stockage et regazéification de gaz naturel, ayant pour but de tripler la capacité de liquéfaction de l'usine, est pratiquement terminée et le début de la production est prévu pour la fin du mois de février 2017. Le 21 décembre 2016, Gaz Métro Plus, une filiale de Société en commandite Gaz Métro, a fait l'acquisition de la participation de Veolia North America, son partenaire dans la coentreprise Société en commandite CDH Solutions & Operations (« CDH ») depuis 2006, pour une contrepartie en espèces de 25,8 millions $, lui conférant ainsi 100 % des parts émises et en circulation et par conséquent le contrôle de cette dernière. À la suite de cette acquisition, la valeur comptable de la participation dans CDH, antérieurement comptabilisée à la valeur de consolidation, a été réévaluée à la juste valeur et en contrepartie, un gain sur réévaluation de 12,5 millions $ est inclus dans le bénéfice net attribuable aux associés de ce secteur pour le premier trimestre de l'exercice 2017. Par conséquent, le bénéfice net attribuable aux associés du secteur Services énergétiques, entreposage et autres s'est élevé à 13,5 millions $ au premier trimestre de l'exercice 2017, comparativement à 1,0 million $ au premier trimestre de l'exercice 2016. CDH détient CCUM, qui possède et exploite un réseau s'étendant sur 3 km utilisé pour le chauffage et la climatisation d'immeubles commerciaux et en copropriété résidentielle et desservant ainsi les besoins énergétiques de 1,8 million de mètres carrés de superficie commerciale au centre-ville de Montréal. À la suite de cette transaction, Gaz Métro Plus devient ainsi l'unique propriétaire de CDH et donc, de CCUM. Gaz Métro entend poursuivre le développement et la croissance de CCUM au cours des prochaines années tout en continuant à offrir une solution énergétique fiable, sécuritaire et à prix concurrentielle à ses clients existants. Le 6 octobre 2016, Gaz Métro inc. a mené à terme un placement privé d'obligations de première hypothèque d'un montant de 125 millions $ portant intérêt au taux annuel de 3,28 % et qui arriveront à échéance le 9 octobre 2046. Le produit de l'émission a été prêté à Gaz Métro à des conditions similaires et a servi à rembourser des dettes existantes et aux fins générales de l'entreprise. Ainsi, le 31 octobre 2016, Gaz Métro inc. a remboursé une série d'obligations de première hypothèque d'un montant de 125 millions $ qui venait à échéance et qui portait intérêt au taux annuel de 10,45 %. Valener tiendra une conférence téléphonique aujourd'hui à 13 h (heure de l'Est) afin de discuter de ses résultats et de ceux de Gaz Métro pour l'exercice clos le 31 décembre 2016. Le public est invité à se joindre à la téléconférence en composant le 647 788-4922 ou sans frais le 877 223-4471. La téléconférence sera également diffusée en direct à partir du site web de Valener (www.valener.com) dans la section « Investisseurs » sous « Événements et présentations » et pourra être réentendue au cours des 365 jours suivant l'appel. Une rediffusion de la conférence téléphonique sera disponible durant une période de 30 jours en composant le 416 621-4642 ou sans frais le 800 585-8367 (code d'accès : 40885898). Valener Inc. est une société ouverte détenue à 100 % par le public investisseur. Elle est le véhicule d'investissement pour le public dans Gaz Métro. Par l'entremise de son investissement dans Gaz Métro, Valener offre à ses actionnaires un placement solide dans un portefeuille énergétique diversifié et en grande partie réglementé, au Québec et au Vermont. En tant que partenaire stratégique, Valener, d'une part participe à la croissance de Gaz Métro, et d'autre part investit conjointement avec cette dernière dans la production d'énergie éolienne au Québec. Valener privilégie des sources et des utilisations d'énergie innovantes, propres, concurrentielles et rentables. Les actions ordinaires et privilégiées de Valener sont inscrites à la cote de la Bourse de Toronto sous le symbole « VNR » dans le cas des actions ordinaires et sous le symbole « VNR.PR.A » dans le cas des actions privilégiées de série A. www.valener.com Comptant plus de 7 milliards $ d'actifs, Gaz Métro est un important distributeur d'énergie. Principale entreprise de distribution de gaz naturel au Québec, elle y exploite un réseau de conduites souterraines de plus de 10 000 km qui dessert plus de 300 municipalités et rejoint plus de 200 000 clients. Gaz Métro est aussi présente au Vermont où elle dessert plus de 310 000 clients. Elle y est active sur le marché de la production et du transport d'électricité et sur celui de la distribution d'électricité et de gaz naturel. Gaz Métro s'implique dans le développement et l'exploitation de projets énergétiques porteurs et novateurs tels que le gaz naturel comme carburant et le gaz naturel liquéfié en remplacement d'énergies plus émissives, la production d'énergie éolienne et la valorisation du biométhane. Gaz Métro est un joueur clé du secteur énergétique qui prend les devants pour répondre aux besoins de ses clients, des régions et municipalités, des organismes communautaires et des collectivités, en plus de répondre aux attentes de ses associés (Gaz Métro inc. et Valener) et de ses employés. www.gazmetro.com Le présent communiqué de presse peut contenir des informations prospectives au sens des lois applicables en matière de valeurs mobilières. Ces informations prospectives tiennent compte des intentions, des projets, des attentes et des opinions de la direction de Gaz Métro inc. (« GMi »), en sa qualité de commandité de Gaz Métro, agissant à titre de gestionnaire de Valener (« la direction du gestionnaire »), et sont fondées sur des renseignements qui sont actuellement à la disposition de la direction du gestionnaire et des hypothèses à l'égard d'événements futurs. Les informations prospectives se remarquent par l'utilisation de mots comme « projette », « s'attend », « estime », « vise », « cible » « prévoit », « a l'intention », « anticipe » ou « croit » ou d'autres expressions similaires, de même que leurs formes négatives et leurs conjugaisons. Les informations prospectives mettent en cause des risques et incertitudes connus et inconnus ainsi que d'autres facteurs indépendants de la volonté de la direction du gestionnaire. Un certain nombre de facteurs pourraient faire en sorte que les résultats réels de Valener ou de Gaz Métro diffèrent de façon importante des résultats historiques ou des attentes actuelles telles qu'elles sont exprimées dans les informations prospectives, notamment, sans limiter la généralité de ce qui précède, la teneur des décisions rendues par les organismes de réglementation, les incertitudes liées à l'obtention par Gaz Métro des approbations des organismes de réglementation et des parties intéressées pour exercer l'ensemble de ses activités et les risques socio-économiques associés à de telles activités, les incertitudes liés à la Politique énergétique du Québec 2030, le caractère concurrentiel du gaz naturel par rapport à d'autres sources d'énergie dans un contexte de fluctuations des prix des produits pétroliers observée à l'échelle mondiale, la fiabilité ou les coûts des approvisionnements en gaz naturel et en électricité, l'intégrité des systèmes de distribution de gaz naturel et d'électricité, l'évolution et la rentabilité de Parcs éoliens de la Seigneurie de Beaupré 2 et 3, Société en nom collectif (« Parcs 2 et 3 ») et de Parc éolien de la Seigneurie de Beaupré 4 S.E.N.C (« Parc 4 ») et d'autres projets de développement, la capacité de Valener de générer suffisamment de liquidités pour soutenir la cible de croissance annuelle anticipée de son dividende ayant trait aux actions ordinaires, la capacité de réaliser des acquisitions attrayantes y compris leur financement et intégration, la capacité de réaliser de nouveaux projets de développement, la capacité d'obtenir du financement dans le futur, la conjoncture économique générale, les fluctuations des taux de change et des taux d'intérêt, les conditions climatiques et d'autres facteurs décrits à la section E « Facteurs de risque de Valener » et à la section R « Facteurs de risque de Gaz Métro » du rapport de gestion de Valener de l'exercice clos le 30 septembre 2016 et les rapports de gestion trimestriels subséquents de Valener qui pourraient traiter de l'évolution de ces facteurs de risque. Bien que les informations prospectives figurant aux présentes soient fondées sur ce que la direction du gestionnaire juge être des hypothèses raisonnables, notamment aucun changement imprévu du cadre législatif et réglementaire du contexte d'exploitation des marchés de l'énergie au Québec et dans les États de la Nouvelle-Angleterre n'aura lieu, les demandes déposées auprès des divers organismes de réglementation seront approuvées telles que soumises, les prix du gaz naturel demeureront compétitifs, l'approvisionnement en gaz naturel et en électricité sera maintenu ou sera disponible à des coûts compétitifs, aucun événement important ne sera survenu autrement que dans le cours normal des activités, tel qu'un désastre naturel, un autre sinistre ou une menace à la cybersécurité (ou cyberattaque), Gaz Métro pourra continuer de distribuer la quasi-totalité de son bénéfice net (excluant les éléments non récurrents), Parcs 2 et 3 et Parc 4 pourront procéder à des versements de distributions à leurs associés, Valener pourra générer suffisamment de liquidités pour soutenir la cible de croissance annuelle anticipée du dividende ayant trait à ses actions ordinaires, Green Mountain Power Corporation aura la capacité de continuer à réaliser des gains d'efficacité et de synergies à la suite de sa fusion avec Central Vermont Public Service Corporation, Valener et Gaz Métro auront la capacité de présenter leurs informations conformément aux PCGR des États-Unis au-delà de 2018 ou adopteront après 2018 des normes internationales d'information financière (IFRS) permettant la comptabilisation d'actifs et de passifs réglementaires, les besoins de liquidités pour les projets de développement de Gaz Métro seront pourvus grâce à une combinaison de flux de trésorerie d'exploitation, d'emprunts sur les facilités de crédit, d'injections de capitaux par les associés et d'émissions de titres de créance et les filiales pourront obtenir les autorisations requises et les fonds nécessaires au financement de leurs projets de développement, ainsi que d'autres hypothèses décrites dans le rapport de gestion de Valener pour l'exercice clos le 31 décembre 2016, la direction du gestionnaire ne peut garantir aux investisseurs que les résultats réels seront conformes à ces informations prospectives. Ces informations prospectives sont présentées à la date des présentes et la direction du gestionnaire n'a pas l'obligation de les mettre à jour ni de les réviser afin de tenir compte de faits nouveaux ou de circonstances nouvelles sauf si les lois sur les valeurs mobilières applicables l'y obligent. Ces informations ne tiennent pas compte des incidences que pourraient avoir un élément inhabituel, un regroupement d'entreprises ou une autre transaction pouvant être annoncés ou pouvant survenir après la date des présentes. Les lecteurs sont priés de ne pas se fier indûment à ces informations prospectives. Des photos, vidéos (B-Roll) et logos de l'entreprise sont disponibles dans la médiathèque.


News Article | February 28, 2017
Site: www.marketwired.com

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Total Energy Services Inc. (TSX:TOT) ("Total") announced today that it has amended its December 9, 2016 offer (the "Original Offer") to purchase all of the issued and outstanding common shares (the "Savanna Common Shares") of Savanna Energy Services Corp. ("Savanna"), to increase the consideration payable thereunder to 0.1300 of a common share of Total (each full common share of Total being referred to in this news release as a "Total Common Share") and $0.20 in cash per Savanna Common Share. Total is in the process of finalizing a notice of change and notice of variation (the "Notice of Change and Variation"), which, among other things, will: (i) amend certain terms of the Original Offer (including to increase the consideration payable for Savanna Common Shares taken-up under the Offer); (ii) update certain information set out in the Original Offer and associated take-over bid circular (the "Original Offer and Circular"); and (iii) supplement information set out in the Original Offer and Circular, including to provide additional context for the Offer and respond to certain assertions made by Savanna in its Directors' Circular dated December 23, 2016 (the "Savanna Circular"). Total expects that the Notice of Change and Variation and an amended letter of transmittal (updated to reflect the additional cash consideration offered by Total and provide for a tax election that Canadian holders of Savanna Common Shares may wish to consider in relation to such cash consideration) will be filed on SEDAR (under Savanna's profile) at www.sedar.com and mailed to registered securityholders of Savanna on or prior to March 1, 2017. In addition to particulars of the increase in the consideration offered by Total, the Notice of Change and Variation will set out various responses to statements made in the Savanna Circular; a number of those responses were included in the news release disseminated by Total on January 10, 2017. The Notice of Change and Variation will also confirm certain legal obligations of Total in respect of the Offer, including obligations relating to the take-up of Savanna Common Shares tendered to the Offer and the filing of a notice of variation and extension (if applicable) of the Offer in the event of a waiver of any conditions to the Offer by Total. As well, the Notice of Change and Variation will provide: (i) updated information concerning the Canadian and United States federal tax ramifications of the Offer to holders of Savanna Common Shares; (ii) further clarification with respect to the rights of Savanna Shareholders resident in the United States; and (iii) additional information to assist those Savanna Shareholders resident in the United States who wish to tender their Savanna Common Shares under the Offer. The Notice of Change and Variation will also contain revised pro-forma consolidated financial statements of Total (the "Updated Pro-Forma Statements"), updated to: (i) give effect to the refinancing transactions completed by Savanna on December 13, 2016; (ii) reflect the increase in the consideration offered by Total under the Offer; and (iii) provide additional detail relating to certain Offer-related expenses, including change of control payments that may become owing to Savanna personnel in the event the Offer is successful. Additional information concerning the Updated Pro-Forma Statements, including certain valuation methodologies used by Total to compile the Updated Pro-Forma Statements, will be set out in the Notice of Change and Variation. Full details of the Offer are contained in the Original Offer and Circular, as amended, varied and supplemented by the Notice of Change and Variation (when filed). Those documents are, or will be, available under Savanna's profile at www.sedar.com and on Total's website at www.totalenergy.ca/savannaoffer. Securityholders of Savanna are urged to read the Original Offer and Circular, the Notice of Change and Variation (when it becomes available), the Letter of Transmittal (and the amended Letter of Transmittal, when it becomes available) and Notice of Guaranteed Delivery for the Offer (collectively, the "Offer Documents") and to consider the important information set out in those documents. Copies of the Offer Documents may be obtained (when they become available in the case of the Notice of Change and Variation and amended Letter of Transmittal) free of charge at www.sedar.com (under Savanna's profile) and may also be obtained free of charge upon request from the Corporate Secretary of Total, at 2550, 300 - 5th Avenue S.W. Calgary, Alberta T2P 3C4, or from Laurel Hill Advisory Group ("Laurel Hill") at the numbers and email address shown below under the heading "Advisors to Total". Total has engaged GMP FirstEnergy to act as its financial advisor and dealer manager. Bennett Jones LLP is acting as Canadian legal advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP is acting as United States legal advisor in connection with the Offer. Laurel Hill Advisory Group ("Laurel Hill") has been retained as information agent for the Offer. Savanna Shareholders may contact Laurel Hill by telephone at 1-877-452-7184 (Toll Free in North America) or 1-416-304-0211 (Collect Outside North America) or by email at assistance@laurelhill.com. Computershare Investor Services Inc. has been retained as the depositary for the Offer. Savanna Shareholders may contact Computershare by telephone at 1-800-564-6253 (Toll free in North America), or at 1-514-982-7555 (Collect Outside of North America), or by e-mail at corporateactions@computershare.com. Total is a growth oriented energy services corporation involved in contract drilling services (Chinook Drilling), rentals and transportation services (Total Oilfield Rentals) and the fabrication, sale, rental and servicing of natural gas compression (Bidell Gas Compression) and process equipment (Spectrum Process Systems). The TSX has neither approved nor disapproved of the information contained herein. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the applicable securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. This news release is not an offer of securities for sale in the United States and the Total Common Shares may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Total Common Shares to be made in the United States will be made by means of a prospectus that may be obtained from Total and that will contain detailed information about Total and it's management, as well as financial statements. Total also intends to file with the U.S. Securities and Exchange Commission ("SEC") a Registration Statement (the "Registration Statement"), which includes the Original Offer and Circular and Notice of Change and Variation, relating to its offer to Savanna Shareholders. TOTAL URGES INVESTORS AND SECURITYHOLDERS TO READ THE REGISTRATION STATEMENT (WHEN IT BECOMES AVAILABLE), THE ORIGINAL OFFER AND CIRCULAR AND NOTICE OF VARIATION (WHEN IT BECOMES AVAILABLE) AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors may obtain a free copy of the Original Offer and Circular and the Notice of Change and Variation (when it becomes available) and other documents filed by Total with the Canadian securities regulators at www.sedar.com (under the issuer profile for Savanna) and, once the Registration Statement is filed, with the SEC at the SEC's website at www.sec.gov . The Original Offer and Circular, the Notice of Change and Variation (when it becomes available) and other documents may also be obtained free of charge from Total's website at www.totalenergy.ca/savannaoffer or upon request made to Total at 2550, 300 - 5th Avenue S.W., Calgary, Alberta T2P 3C4. Securityholders should be aware that Total may purchase Savanna Common Shares otherwise than under the Offer, such as in open market purchases. This news release contains certain forward-looking information (referred to herein as "forward-looking statements"). Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "believe", "plan", "scheduled", "intend", "objective", "continuous", "ongoing", "estimate", "expect", "may", "will", "project", "should", or similar words suggesting future events, circumstances or outcomes. In particular, this news release contains forward-looking information concerning the Offer and the anticipated content, filing and mailing of the Notice of Change and Variation, amended letter of transmittal and Registration Statement. Forward-looking statements are based upon the opinions and expectations of management of Total as at the effective date of such statements. Although Total believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that those expectations will prove to have been correct. Forward-looking statements are subject to certain risks and uncertainties that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, such things as changes in general economic conditions in Canada, the United States and elsewhere, the volatility of prices for oil and natural gas and other commodities, fluctuations in currency and interest rates and fluctuations in market prices for the publicly traded securities of Total and Savanna, non-fulfillment of conditions of the Offer and new laws and regulations (domestic and foreign). The forward-looking statements made in this news release are based upon various assumptions and factors, including publicly reported information concerning Savanna, that Savanna has made full and accurate disclosure of all material information concerning Savanna in accordance with applicable Canadian securities laws (including disclosure of all material contracts and existing and potential contingent liabilities), that there have been no material changes in the business, affairs, capital, prospects or assets of Savanna since September 30, 2016, except as announced by Savanna on November 22, 2016, November 28, 2016, December 13, 2016, December 23, 2016 and January 10, 2017. Having regard to the various risk factors, readers should not place undue reliance upon the forward-looking statements contained in this news release and such forward-looking statements should not be interpreted or regarded as guarantees of future outcomes. The forward-looking statements contained in this news release are made as of the date hereof and Total does not undertake any obligation to update or to revise any of the included forward-looking statements, except as required by applicable securities laws in force in Canada. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.


SHANGHAI, China and CUPERTINO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Tony (Bizuo) Liu, Chief Executive Officer of the Company, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017, at 9:30 a.m. Eastern Time, at the Waldorf Astoria Hotel in New York City. A live audio webcast of the presentation will be available on the company's website at http://www.cellbiomedgroup.com/investor-relations/presentations/. Webcast replay will be available one hour after conclusion of the live event. About Cellular Biomedicine Group (CBMG) Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.


CARLSBAD, CA / ACCESSWIRE / March 2, 2017 / Isodiol, the Southern California-based hemp cannabinoid innovator, manufacturer, and CBD wholesale retailer, is proud to announce their participation in the 3rd Annual Spring Cannabis Business Expo. Isodiol's presence in this leading forum, March 5-8, reflects the Company's ever-expanding role in the international cannabis marketplace. Isodiol's revolutionary nano-amplified cannabinoids and crystalline CBD formulas are added to consumer products and supplied to manufacturers as bulk ingredients. The Company's products contain no THC and are derived from the mature stalk of the industrial hemp plant and, therefore, can be shipped anywhere in the world. "We are thrilled to get to be a part of the California Cannabis Business Expo right here in San Diego," says Isodiol CEO, Jared Berry. "As innovators with a global presence in the hemp cannabinoid consumer and manufacturing market, we look forward to sharing our industry experience and proprietary developments with expo attendees and participants from around the world." The Expo is produced by MJIC Media and sponsored by the Marijuana Investor Summit. In just three years since its inception, this annual forum has earned a reputation as a leading event in what promises to be a multi-billion dollar industry in the United States. MJIC Media chose the Sheraton Marina in San Diego for this year's expo, tapping into the dense population of Southern California. With the passage of Proposition 64 in the state, Expo organizers look forward to building on the momentum of the area's burgeoning cannabis industry and providing the highest quality networking and education for participants. A key component to Isodiol's continually growing relationships with consumers, wholesalers, and manufacturers is the quality and consistency of their pharmaceutical grade CBD finished products and bulk goods. Featured products appeal to these markets. Nanotechnology powers several of Isodiol's products. CBD NaturalsTM bottled nano-amplified hemp CBD water contains cellular nutrients and cannabidiol for powerful hydration. VitaDots CBD gummies deliver HeneplexTM, a full spectrum hemp essential oil complex with naturally occurring, non-psychoactive phyto­cannbinoids like Cannabidiol (CBD) and over 75 botanical terpenes. They come in two formulas/flavors, one for immune and bone health and one for digestive support. NanoDrops Beverage Enhancer is also powered by HeneplexTM and is a convenient way to add cannabinoid support to any liquid. CBDXtremeTM delivers TruSpectrumTM full-spectrum hemp oil in a variety of innovative delivery systems. VAPEIt formulas combine phytocannabinoids and adaptogenic herbs in tasty blends. DABIt Crumble, Distillate, and Isolate formulas provide options for full-spectrum phytocannabinoid and extreme CBD benefits. The versatile ADDit hemp oils deliver the full-spectrum of phytocannabinoids. CHEWIt provides vitamins and pre/probiotic support in these all-natural CBD gummies. Isodiol's bulk products are impacting the international market. Pure CBD Isolate is refined 99%+ pure CBD in a crystalline formula for consumer and manufacturing needs. Labeled as CBD99TM, it is the first hemp-derived Isolate to enter the marketplace. Its reputation as the highest quality crystalline available placed it in demand as the most widely used naturally sourced CBD for medical studies. Derived from the industrial parts of the hemp plant and available for distribution through the USA and internationally, this Isolate is Kosher certified and produced in a GMP and ISO 9001 certified facility. It is sourced completely from ECO certified (European Organic Certification) Hemp. Nano Concentrates are also powerful options for nanoemulsified Cannabidiol delivery. CebidiolTM revolutionizes skin delivery technology with microencapsulated CBD. The microscopic spheres release layer by layer for time-released delivery. HeneplexTM is a universal, water-based additive. Its unique synergistic blend of over 75 botanical terpenes and 25,000mg/liter of non-psychoactive Cannabidiol (CBD) can be easily incorporated into a wide array of formulations, offering manufacturers competitive advantage when it comes to cost and product efficacy. CBDNanoUltraTM contains 20,000mg/liter of Cannabidiol and is also a water-soluble additive. CBD Oils are formulated with pure pharmaceutical grade CBD, organic certified hemp seed oil, and organic certified coconut oil. CBD50, CBD100, CBD150, and CBD250 (varied concentrations) are available in 10ml and 1L sizes. CannaCeuticals offers the purest cosmeceutical grade CBD skincare in their CBD7 complete anti-aging collection. Last week, Isodiol granted an exclusive distribution agreement to Laguna Blends, Inc. (CSE: LAG) (OTC PINK: LAGBF) (Frankfurt: LB6A.F) for Canada. The Company will provide its experience in research, development and manufacturing to support Laguna's vibrant growth, offering all of its current products on an exclusive basis for the Canadian market. Receiving the Best CBD Company of the Year Award at the World of Cannabis Expo in Las Vegas just six months ago, Isodiol is committed to continually building upon their solid reputation and track record. Isodiol's COO Troy Nihart says, "We continually forge new territory, creating the most innovative CBD infused consumer products and raw ingredients for manufacturing and our business-to-business relationships. We look forward to showcasing some of our finest products and brands at SBCC." Isodiol and its team of collaborators are a group of companies that together, grow and harvest hemp on an industrial scale, and then process it to extract the non-psychoactive cannabidiol (CBD) to the highest available purity for worldwide distribution. By utilizing one of the world's largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high-grade, non-psychotropic CBD. Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due to its products. Isodiol's proprietary purification process is ISO 9001 certified. This federal certification holds the company, processes, and products to the highest of standards. To follow Isodiol online, visit the Company's website at http://www.isodiol.com or Facebook, Instagram, and Twitter. CBDXtremeTM, partnered with TruSpectrumTM, creates superior full-spectrum hemp oil products to support the wellness efforts of people everywhere. Harnessing the finest technology and cutting-edge science, TruSpectrumTM delivers the range of cannabinoids present in the original hemp plant. These hemp oil supplements provide the entourage effect, in which all of the oil's components work together for maximum benefits. The hemp oil in CBDXtremeTM products also provides many important vitamins and minerals, essential fatty acids, fiber, protein, chlorophyll, flavonoids, and terpenes. CBDXtremeTM works with the finest cultivators in the industry, ensuring their full-spectrum hemp oil is derived only from specific cultivars of hemp that contain an abundance of cannabinoids. Follow the company here: https://cbdxtreme.com/ or Instagram, and Facebook. Created by a team of doctors, the unique formulations in CBD NaturalsTM and delivers hydration and cellular nutrients in the most bioavailable form possible. Powered by quantum physics, the nanotechnology behind the formulation in this water makes the cannabinoid particles small enough for the body to use virtually 100 percent of them for optimal cannabinoid wellness support. To follow CBD NaturalsTM online, visit the company's website or social media: Instagram, Facebook. Laguna Blends is a market leader in the distribution of Hemp and CBD products. Laguna's growth strategy includes acquiring and incubating companies who formulate and or manufacture Hemp products. Laguna Blends markets Hemp products utilizing its B-to-B Network along with driving traffic to its Laguna Blends online marketplace. It is Laguna's intent to provide the highest quality hemp product experience for the end user, utilizing a proprietary nanotechnology in many of its consumable and topical skin care products. Laguna is currently seeking joint ventures and acquisitions to expand its portfolio and will aggressively begin international expansion into Asia and Europe in 2017. To follow Laguna Blends online, visit the company's websites or social media: https://lagunablends.com/ or https://cbdskincream.com/ Facebook: https://www.facebook.com/LagunaBlends/ Twitter: @LagunaBlends This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release. Any and all statements made in this article in regard to Isodiol and its CBD/Cannabidiol products are not expressed as medical claims. Our intention is to initiate conversation, not to suggest results nor to encourage action on the part of the reader. Isodiol is not responsible for, and expressly disclaims all liability for, damages of any kind arise out of use, reference to, or reliance on any information contained herein. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, or cure any disease. Always check with your physician before starting a new dietary supplement program. Isodiol does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Cannabidiol is a natural element of industrial hemp. Isodiol's products are not intended to cure, treat or mitigate any disease states.


TORONTO, ON / ACCESSWIRE / February 28, 2017 / Drone Delivery Canada Corp. (CSE: FLT) (OTC PINK: ASRCF) ("DDC" or the "Company"), is pleased to announce, further to its news releases dated February 6, and February 23, 2017, that it has completed its previously announced private placement offering of special warrants (the "Special Warrants"), issuing an aggregate of 31,144,000 Special Warrants at a price of $0.35 per Special Warrant for aggregate gross proceeds of $10,900,400, which includes the exercise by GMP Securities L.P. ("GMP"), as sole lead agent, of its option for an additional 1,144,000 Special Warrants. This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements. For more information, please visit www.dronedeliverycanada.com. Drone Delivery Canada is a drone technology company focused on the design, development, and implementation of its proprietary logistics software platform utilizing drones. The Company's platform will be used as Software as a Service (SaaS) for government and corporate organizations. Drone Delivery Canada Corp. is a publicly listed company trading on the Canadian Securities Exchange under the symbol FLT. Certain information set forth in this news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law. THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.


News Article | February 22, 2017
Site: marketersmedia.com

Thomas D’Innocenzi, Founder of Nova Advisors has announced a unique consulting service that allows small and medium size enterprises to compete globally and rapidly grow market share cost effectively. The Global Sourcing and Business Development service will utilize their locations in Asia and the United States along with a very large network of buyers and suppliers that has been developed over 25 years. “Having built and managed sourcing and business teams for large companies throughout my career, I recognized an opportunity to offering a more streamlined and cost effective service that would allow companies to compete globally where they could not budget for it before” explained Founder and Principal Consultant Thomas D’Innocenzi. “Up until now, the ability to setup a Global Sourcing operation in Asia for low cost contract manufacturing solely belonged to large corporations that had the capital. In addition, the ability to market goods and services into large regions such as Southeast Asia with a population of 700 million solely belonged to large corporations that had the capital. Now, I give small to medium size enterprises the ability to compete in Global Sourcing and Business Development in Southeast Asia, China and beyond with our ability to leverage our network, locations, contacts, and knowledge to quickly gain market share at a much lower cost threshold.” The Business Development segment of the service in Asia and the US includes rep office creation and management, salesforce development, product regulatory compliance, local legal support, local branding, local advertising, sales and product support, market planning, competitive analysis. The Global Sourcing segment of the service which addresses the whole Asia-Pacific region includes product specification management, supplier vetting (identification, regulatory compliance, GMP, ISO, QA, QC), backup supplier and risk management, pricing and contract negotiations, commodity tracking, category management, product management, creation and management of local Asian global sourcing offices. The Southeast Asia location offers US and European customers an immediate local presence when utilizing the new service for either Business Development of Global Sourcing in Asia. The Bangkok-based office has easy reach through SE Asia and China and is very cost effective in operation. Areas serviced from this location include Shanghai, Seoul, Hong Kong, Bangkok, Ho Chi Minh, Vientiane, Kuala Lumpur, Singapore, Manila, Cebu. The US office location offers Asia-based clients a cost-effective US market entry point for their products or services. We understand the needs of the local Asian culture and the business acumen of US buyers and we create and execute a methodology of closing deals that are mutually beneficial and promotes trade. Based in Jacksonville, Florida and Bangkok, Thailand, Thomas D’Innocenzi, Founder and Principal Consultant of Nova Advisors helps companies compete globally by offering expert Global Sourcing and Business Development consulting services. Mr. D’Innocenzi has over 30 years of experience in international trade and business development with multinational corporations in the US and Asia. He has worked and lived in several countries in the Asia Pacific region. With locations in the United States and Asia and with a large global network of buyers and suppliers, Mr. D’Innocenzi offers a value-added unique service for customers seeking to effectively expand their market footprint globally while managing risk. More information about the business can be found at http://www.novaadvisors.com. Contact phone numbers are United States: +1.904.307.6414 and Asia: +668.7.800.1015 For more information, please visit http://www.thomasdinnocenzi.com/


News Article | February 21, 2017
Site: www.prnewswire.co.uk

Anlit Ltd., part of the Maabarot Products Ltd., launches vegetarian curcumin gummies for consumers seeking curcumin supplement alternatives. Anlit will present this supplement and other novel products at Vitafoods Europe-FPE, May 9-11, 2017, in Geneva. The new turmeric gummy supplement contains natural colourants, without preservatives or artificial colours. It has a delicious natural orange flavour, presented in either a teddy bear or star shape. Most gummies contain gelatin, but the growing demand for vegetarian products, together with the fact that all Anlit products are certified kosher and halal, led the company to replace gelatin with pectin. Anlit's gummy technology overcomes the challenges of the unpleasant flavor and aroma associated with many curcumin supplements. It provides a tasty, healthy solution for kids and adults. Anlit uses a unique technology to produce the pectin-based turmeric gummy by using a clean, starch-free, molding system forming a tender, textured gum. "There are only a few turmeric gummies in the marketplace, but Anlit's unique technology allows for the incorporation of a substantial dose of curcumin-30 mg-in synergy with 150 mcg of piperine per gummy, without affecting taste or texture," says Shai Karlinski, VP of sales and marketing for Anlit. "I encourage Vitafoods' visitors to come to our booth and taste these delightful, healthful gummies." The turmeric gummy is an easy and fun way to consume a beneficial curcumin dosage, without the need to swallow tablets or capsules. "Consumers are concerned about additives such as synthetic colourants or preservatives and so are more likely to buy our gummies," adds Karlinski. "The gummies are available to retailers and food supplement manufacturers for marketing under a private label." Anlit Ltd. is a subsidiary of Maabarot Products, Israel, a public company traded on the TASE. The company continues to strengthen its competitive lead through cutting-edge advancements and the creation of high-quality products. Anlit is an innovative manufacturer of a broad range of dietary supplements developed for children and adult. Anlit products are gluten-free and nut-free. All products are GMP, FSSC, ISO 9001:2000 and HACCP compliant, as well as kosher and halal certified. Visit us at Finished Products Europe (VitaFoods), Booth No. M118

Loading GMP collaborators
Loading GMP collaborators